The evolving role of adjuvant immune checkpoint inhibitors in urothelial carcinoma

Key Points

• Immune checkpoint inhibitors improve overall survival in urothelial carcinoma patients.
• Key evidence indicates a 40% reduction in disease recurrence with these therapies.
• Assessment of tumor microenvironment and biomarkers guides the use of adjuvant therapy.
• The findings highlight a need for further multi-center trials in diverse populations.